Cholinesterase inhibitors such as galantamine, donepezil, and rivastigmine, appear to generate persistent cognitive benefits, and increased longevity for up to five years in Alzheimer's patients.
Cholinesterase inhibitors such as galantamine, donepezil, and rivastigmine, appear to generate persistent cognitive benefits, and increased longevity for up to five years in Alzheimer's patients.